Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica - 1 Oct 2013

Shiose Yoshinobu

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Class I Phosphatidylinositol 3-Kinases
Share to Drug Discovery
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphoinositide-3 Kinase Inhibitors

Share to PTEN Phosphohydrolase

Share to Quinolines

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 24107518
DOI: 10.1254/fpj.142.156

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy].PMID 24107518Read ↗

Current State and Future Challenges for PI3K Inhibitors in Cancer TherapySemantic proximity Read ↗

Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.Semantic proximity Read ↗

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsSemantic proximity Read ↗

[PI3K and mTOR pathway and molecular targeted agents].Semantic proximity Read ↗

Targeting PI3K in cancer: mechanisms and advances in clinical trialsSemantic proximity Read ↗

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and ImmunotherapySemantic proximity Read ↗

New phosphatidylinositol 3-kinase inhibitors for cancer.Semantic proximity Read ↗

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.Semantic proximity Read ↗

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway InhibitorsSemantic proximity Read ↗

Challenges in the clinical development of PI3K inhibitors.Semantic proximity Read ↗

Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020).Semantic proximity Read ↗

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.